Anne Finucane Disposes 7,500 CVS Shares; Form 4 Corrects Late Report

Rhea-AI Filing Summary

Anne A. Finucane, a director of CVS Health (CVS), reported a sale of company stock that was filed on Form 4. The filing shows a transaction dated 08/20/2025 in which 7,500 shares of Common Stock were disposed of at a reported price of $71.02 per share under transaction code S(1). After the reported sale, the filing lists 22,156 shares beneficially owned indirectly through a trust. The form includes an explanatory note stating the sale was not timely reported due to an administrative error. The document is signed by Anne M. Finucane on 08/29/2025.

Positive

• Corrective disclosure provided: the Form 4 explicitly acknowledges the late report and documents the transaction
• Specific transaction details disclosed: number of shares (7,500), price ($71.02), date (08/20/2025), and post-transaction indirect holdings (22,156)

Negative

• Late reporting of the sale, described as an administrative error
• No additional context about the reason for the disposition beyond the administrative-error explanation

Insights

Corporate Governance Expert

TL;DR: Director sold 7,500 CVS shares; late filing cited as an administrative error—no additional material disclosures in this Form 4.

The transaction is a routine insider sale by a director with the filing indicating indirect ownership via a trust. The filing explicitly notes the late reporting resulted from an administrative error; no other changes to ownership structure, options, or derivative positions are disclosed. For investors, this Form 4 provides transparency on a specific sale and the director's remaining indirect stake of 22,156 shares. The entry is factual and limited in scope.

Securities Compliance Analyst

TL;DR: Single reported disposition of 7,500 shares at $71.02; corrective Form 4 documents the late reporting.

The filing documents corrective reporting rather than new or complex transactions. Key compliance detail is the explanatory statement acknowledging the sale was not timely reported because of an administrative error, which is relevant for disclosure controls but does not itself state a regulatory finding or penalty. The Form identifies the reporter as a director and shows the transaction code S(1) for the sale. No derivative transactions were reported on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finucane Anne A.

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RI 02895

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		S(1)		7,500	D	$71.02	22,156	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares by the reporting person not timely reported due to an administrative error.

	/s/ Anne M. Finucane	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Anne A. Finucane report on the Form 4 for CVS (CVS)?

The Form 4 reports a sale of 7,500 shares of CVS common stock on 08/20/2025 at a price of $71.02 per share, leaving 22,156 shares beneficially owned indirectly by a trust.

Why was this Form 4 filed late for CVS (CVS)?

The filing includes an explanation stating the sale was not timely reported due to an administrative error.

What is the reporting person's relationship to CVS in this Form 4?

The reporting person, Anne A. Finucane, is identified as a Director of CVS Health.

Does the Form 4 show any derivative transactions for CVS (CVS)?

No. Table II for derivative securities contains no entries; only a non-derivative sale of common stock is reported.

When was the Form 4 signed and submitted for this transaction?

The form is signed by Anne M. Finucane and dated 08/29/2025.